Y chromosome loss in chronic myeloid leukemia detected in both normal and malignant cells by interphase fluorescence in situ hybridization
✍ Scribed by Judy A. Kirk; Donald R. Vandevanter; Jennifer Biberman; Eileen M. Bryant
- Publisher
- John Wiley and Sons
- Year
- 1994
- Tongue
- English
- Weight
- 878 KB
- Volume
- 11
- Category
- Article
- ISSN
- 1045-2257
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Loss of the Y chromosome in bone marrow (BM) cells is a normal age‐associated event. Y chromosome loss is also observed in the Philadelphia chromosome (Ph) positive BM cells of some patients with chronic myeloid leukemia (CML) in chronic phase, but at a younger age than in normal individuals. While the significance of loss of the sex chromosome in normal males is uncertain, ‐Y marrow cells are not believed to be of clonal origin. However, because CML is a clonal disease, CML sub‐populations with Y loss may constitute a disease‐related sub‐clone. We used a PCR‐amplified yeast artificial chromosome containing the BCR gene region for single color interphase analysis of BCR rearrangement by fluorescence in situ hybridization (FISH). Then, using two color FISH, with one fluorochrome detecting the BCR gene region and the other detecting Y chromosome repeat sequences, we surveyed peripheral and BM Y loss in both normal Ph‐ (BCR not disrupted) and CML Ph+ (BCR rearranged) interphase nuclei of two patients with Y loss in Ph positive cells observed by metaphase analysis. ‐Y was seen in a proportion of Ph+ cells in both cases, and the proportion matched that seen in Ph‐ cells, indicating that Y loss is probably sporadic in both normal and CML populations, and that the propensity for Y loss in normal BM cells may be a phenotype that can be retained by malignant cells in CML.
📜 SIMILAR VOLUMES
Abnormalities of chromosome 14 involving band q32.33 are among the most commonly observed cytogenetic alterations in B-cell malignancies. To assess the incidence and pathogenetic implications of 14q32.33 translocation in chronic B-cell leukemia/lymphomas, we performed fluorescence in situ hybridizat
## Abstract Fluorescence in situ hybridization for the __BCR__/__ABL__ rearrangement in 138 bone marrow specimens from 59 Philadelphia^+^ (Ph^+^) chronic myelogenous leukemia (CML) patients, 35 Ph^+^ acute lymphoblastic leukemia (ALL) patients, and 57 Ph^−^ ALL patients was used. Sixteen (27.1%) of